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Autophagy protease ATG4B is a key regulator of the LC3/GABARAP conjugation
system required for autophagosome formation, maturation and closure. Members of
the ATG4 and the LC3/GABARAP family have been implicated in various diseases
including cancer, and targeting the ATG4B protease has been suggested as a potential
therapeutic anti-cancer strategy. Recently, it has been demonstrated that ATG4B is
regulated by multiple post-translational modifications, including phosphorylation and
de-phosphorylation. In order to identify regulators of ATG4B activity, we optimized a cell-
based luciferase assay based on ATG4B-dependent release of Gaussia luciferase. We
applied this assay in a proof-of-concept small molecule compound screen and identified
activating compounds that increase cellular ATG4B activity. Next, we performed a high-
throughput screen to identify kinases and phosphatases that regulate cellular ATG4B
activity using siRNA mediated knockdown and cDNA overexpression. Of these, we
provide preliminary evidence that the kinase AKT2 enhances ATG4B activity in cells. We
provide all raw and processed data from the screens as a resource for further analysis.
Overall, our findings provide novel insights into the regulation of ATG4B and highlight
the importance of post-translational modifications of ATG4B.
Keywords: ATG4B, siRNA, small molecule, kinase, phosphatase, cDNA, screen, AKT2
INTRODUCTION
Autophagy is a cellular process central to multiple aspects of health and disease. A key function
of autophagy is to mediate lysosomal degradation of cellular material through the formation of
an autophagosome, a double-membrane structure that engulfs cytoplasmic material, seals it from
the surrounding cytoplasm and delivers it to the lysosome. The formation of an autophagosome
is governed by a number of ATG (AuTophaGy-related) proteins that are conserved from yeast to
mammalian cells (Tsukada and Ohsumi, 1993).
A key step in the formation of an autophagosome is the conjugation of microtubule-
associated protein 1 light chain 3 (LC3) and gamma-aminobutyric acid receptor-associated protein
(GABARAP) proteins to the autophagosomal membrane. LC3/GABARAP proteins are synthesized
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in the cell as an inactive form (pro-LC3/GABARAP) that require
activation through C-terminal proteolytic cleavage by the ATG4
family of proteins to generate LC3/GABARAP-I.
It is thought that ATG4 mediates two key processing
steps of LC3/GABARAP, the proteolytic processing prior
to lipidation and insertion of lipidated LC3/GABARAP-II
in the autophagosomal membrane, and the de-lipidation
of LC3/GABARAP-II, leading to recycling of processed
LC3/GABARAP-I. There are four members of the ATG4 family
in mammalian cells that are partially redundant in substrate
processing, but have also distinct specificities. ATG4B, the
main isoform of the ATG4 family of proteins is regulated by
different types of post-translational modifications, including
ubiquitination (Kuang et al., 2012), O-GlcNAcylation (Jo
et al., 2016), S-nitrosylation (Li et al., 2017), capase mediated
proteolysis (Betin and Lane, 2009; Betin et al., 2012), redox
mechanisms (Scherz-Shouval et al., 2007; Qiao et al., 2015;
Heintze et al., 2016) and phosphorylation (Yang et al., 2015;
Huang et al., 2017; Pengo et al., 2017; Sanchez-Wandelmer et al.,
2017; Ni et al., 2018). It is not well understood how ATG4B
hydrolase activity toward its two substrates pro-LC3 and LC3-II
could be differentially regulated, but recently it has been pointed
out that post-translational modifications may control the ATG4B
proteolytic and de-lipidation activity. It has been shown that local
phosphorylation by ATG1/ULK1 at the forming autophagosome
inhibits ATG4 activity in yeast (Sanchez-Wandelmer et al.,
2017) and ATG4B in mammalian cells (Pengo et al., 2017),
whereas de-phosphorylation by PP2A renders ATG4B active in
the cytoplasm of cells. Other phosphorylation events may also
contribute to such regulation, since AKT1 and MST4 are capable
of phosphorylating ATG4B (Huang et al., 2017; Ni et al., 2018),
although the spatio-temporal context of this has not yet been
defined.
A role for ATG4B in cancer has been proposed, including
chronic myeloid leukemia (Rothe et al., 2014), osteosarcoma
(Akin et al., 2014), colorectal cancer (Liu et al., 2014), prostate
cancer (Mouratidis et al., 2014), breast cancer (Bortnik et al.,
2016) and pancreatic adenocarcinoma (Yang et al., 2018). The
rationale that ATG4 proteins might be therapeutic targets mostly
stems from the fact that these proteins are highly over-expressed
in some cancer types compared to non-cancerous cells (Costa
et al., 2016) and genetic inhibition of ATG4B either through
siRNA or use of a dominant negative form of the gene show some
benefit in chronic myeloid leukemia (Rothe et al., 2014), breast
cancer (Bortnik et al., 2016) and pancreatic carcinoma (Yang
et al., 2018).
Multiple efforts are underway to develop biochemical assays to
monitor ATG4B activity and thus identify compounds targeting
ATG4B (Kurdi et al., 2017). Assay types include the use of
enzymatic reporter genes, such as the phospholipase A2-linked
substrate approach (Ni et al., 2015), amino-methylcoumarin
(AMC)-type esters of LC3 substrates, BRET-based assays (Woo
et al., 2014), and gel electrophoresis assays (Cleenewerck et al.,
2016).
We have previously developed a cell-based system to monitor
cellular ATG4B activity that utilizes the non-conventional
secretion of a small luciferase (Ketteler et al., 2008; Luft et al.,
2014). Key advantages of this assay are that it is very sensitive,
non-invasive and highly quantitative (Ketteler and Seed, 2008).
This assay has supported significant discoveries that helped to
understand the post-translational regulation of ATG4B. These
include the identification of the ubiquitin ligase RNF5 as a
key regulator of ATG4B stability (Kuang et al., 2012), the
O-GlcNAc modification of ATG4B to increase its proteolytic
activity (Jo et al., 2016), and the regulation of ATG4B activity
by phosphorylation (Yang et al., 2015; Pengo et al., 2017). Here,
we present a small molecule and siRNA screen to identify
regulators of ATG4B activity in cell-based assays. The identified
compounds are effective to overcome cancer-associated defects
in LC3A processing and are valuable tool compounds for further
development and understanding of ATG4 biology. Furthermore,
we have identified a number of kinases that modulate ATG4B-




HeLa cells expressing mCherryLC3 were obtained from
Dr. Ramnik Xavier (Massachusetts General Hospital, Boston).
Retroviral supernatants of HEK293T cells transfected with
pMOWS-ActinLC3dNGLUC, GagPol and VSV-G were obtained
by calcium phosphate precipitation as described (Ketteler et al.,
2002) to generate stable HeLa ActinLC3dNGLUC/mCherryLC3
and HEK293T-ActinLC3dNGLUC cells. Briefly, pBABE-
mCherry-GFP-LC3 or pMOWS-ActinLC3dN was transfected
with VSV-G and GagPol into HEK293 cells using calcium
phosphate transfection. Supernatants were harvested and filtered
through 0.45 µm filters, supplemented with 8 µg/ml final
concentration of polybrene (Sigma) and added to target cells
for overnight incubation. Transduced cells were then passaged
and selected with puromycin. All cell lines were cultured in
Dulbecco’s Modified Eagle Medium (DMEM) supplemented
with 10% fetal calf serum (FCS, Life Technologies), L-Glutamine
and Penicillin/Streptomycin.
Plasmids
Expression plasmids pGEXATG4B and pGEXATG4BC74S
were created as described previously (Pengo et al., 2017).
pGEXATG4B11−24 (mutation by deletion of 24 amino
acid residues from the N-terminus), pGEXATG4BS34A,
pGEXATG4BS34D and pGEXATG4BS121A were created by
PCR using pGEXATG4B as a template and primers 11–24
forward (5′-CCC GTT TGG ATA CTG GGT AGA AAA TAC
AGC-3′) and 11–24 reverse (5′-GAA TTC CGG GGA TCC
CAG GGG C-3′), primers S34A forward (5′-GCT ATT TTC
ACA GAA AAG GAC GAG-3′) and S34A reverse (5′-GTA TTT
TCT ACC CAG TAT CCA AAC-3′), primers S34D forward
(5′-GAT ATT TTC ACA GAA AAG GAC GAG-3′) and S34D
reverse (5′-GTA TTT TCT ACC CAG TAT CCA AAC-3′),
primers S121A forward (5′-GCT TAC TAC TCC ATT CAC
CAG ATA-3′) and S121A reverse (5′-GTC CTT CCT GTC GAT
GAA TGC GTT-3′), and primers S262A forward (5′- GCA GCC
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CAC TAC TTC ATC GGC TA-3′) and S262A_reverse (5′- GTT
GGG CTT CCC TCC GAT GAC-3′), respectively. All PCR were
performed at 30 cycles using Pyrobest DNA polymerase (Takara,
R005A). The PCR products were phosphorylated, ligated and
transformed into Escherichia coli DH5α for selection of correct
plasmids. The following constructs were described elsewhere:
pMOWS-ActinLC3dN (Ketteler et al., 2008), pGEXCLK2cd
(Prak et al., 2016), pEAK12-ActinLC3A-R70H-dNGLUC (Costa
et al., 2016), and pEAK12-GFP (Ketteler et al., 2008). The ATG4B
promoter construct ATG4B-FLUC was obtained from Switchgear
Genomics (#S711306). The sequence of the inserted promoter
region from ATG4B is shown in Supplementary Figure S1.
The vector map can be found on the company’s website1.
Transcriptional activation of ATG4B promoter was measured
by monitoring Renilla luciferase in cell lysates according to the
manufacturer’s instructions (Promega).
Compounds
The Chemibank compound collection was obtained from David
Selwood2. The ranges of some of the molecular properties are as
follows: molecular weight between 126 and 600, AlogP between
−3.5 to 6, hydrogen bond donors between 0 and 6, hydrogen
bond acceptors between 0 and 12, rotable bonds between 0 and
15 and number of rings between 1 and 8. The library has hit-like
properties (rule of 6) and falls just outside the Lipinski’s rule of
five. A total of 30,000 compounds was stored as a 10 mM DMSO
stock solution under nitrogen (5% O2) and low humidity (5%) at
room temperature and in the dark (Roylan San Francisco storage
pod). For screening, compounds were transferred to assay plates
using the Labcyte Echo 520 at a final concentration of 10 µM with
a final DMSO concentration of 0.2%. Hit compounds were re-
purchased from Asinex (Delft, Netherlands), or Life Chemicals
(Ukraine). Bafilomycin A, DTT, H2O2, N-acetyl cysteine and
rapamycin were obtained from Sigma.
Small Molecule Screening
High-Throughput Screening was performed in 384-well plates
(Greiner). First, compound was added to the plates using
the Echo 520 (Labcyte). Next, HeLa-ActinLC3dNGLUC cells
(20,000/well) were dispensed onto the compounds using the
Thermo Fisher Multidrop and cultured for 24 h at 37◦C.
Supernatants (5 µl) were harvested and dispensed into black
384-well plates. Native coelenterazine (Cambridge Bioscience,
#BT10110) in GLUC buffer (0.1% disodium phosphate, 5%
glycerol, 150 mM sodium bromide, 1 mM EDTA, 25 mM Tris-
HCL pH8 and 2 mM ascorbic acid) at a final concentration of
10 µg/ml was injected immediately prior to analysis using the
Envision II (PerkinElmer) plate reader. For Z′ factor calculation,
the following formula was used:
Z′ = 1 − (3x(STDpos + STDneg)/|meanpos − meanneg|)
1www.switchgeargenomics.com
2www.ucl.ac.uk/chemibank
with STDpos = standard deviation of the positive control and
STDneg = standard deviation of the negative control. For cell-
based assays, we accept values that are higher than 0.3 for the Z′
factor.
siRNA and cDNA Screening
Stable HEK293T-ActinLC3dNGLUC were sent for STR profiling
and confirmed as HEK293T cells. Cells were counted and 5,000
cells were seeded into 384-well and incubated overnight at
37◦C and 5% CO2. The siRNA library for human kinases and
human phosphatases (Sigma MISSION, Supplementary File S1)
consists of 3 siRNA oligonucleotides per gene in a 96-well format
where the outer columns 1 and 12 were used for controls. First,
the 3 siRNAs for each gene were pooled using the automated
Tecan Freedom Evo liquid handler. The siRNA pools were then
transfected at a final concentration of 55 nM with lipofectamine
2000 (Invitrogen) using an automated protocol on the Tecan
Freedom Evo in 384-well plates. Briefly, 5 µl of the siRNA
stock solution (100 µM) was mixed with 0.5 µl lipofectamine
and 50 µl Optimem for 20 min at RT. Ten µl of this mixture
was added to cells in the 384-well plate to a total volume
of 50 µl and incubated for 48 h at 37◦C. After 48 h, 5 µl
of supernatant was transferred using the Tecan Freedom Evo
to black 384 multi-well plates and 25 µl substrate of native
coelenterazine was added prior to reading luminescence in the
PerkinElmer Envision II. Substrate was added using the injectors
of the PerkinElmer Envision II to ensure equal times from
addition of substrate to measurement in all wells. The cDNA
kinome library (Supplementary File S2; Thermo Fisher) was
transfected at 100 ng/well in HEK293T cells stably expressing the
ActinLC3dNGLUC reporter and luciferase release was monitored
after 24 h.
Statistical Analysis
The primary screening data was analyzed using CellHTS2
(Boutros et al., 2006). Relative luciferase light units were
normalized across the plate and the B scores were calculated
to determine Z scores of each individual compound. All
error bars shown unless otherwise indicated are calculated
as standard deviations from the mean of the replicates.
Statistical significance was calculated using a two-sided
paired T-Test (Microsoft Excel). In Figure 3C, a one-way
ANOVA with Tukey’s multiple comparison test was applied
to calculate significances. The graph was drawn in GraphPad
Prism.
Luciferase Release Assay
The luciferase release assay was described previously (Ketteler
et al., 2008). Native coelenterazine was prepared as 1 mg/ml
stock solution in acidified Methanol and diluted 1:100 in PBS
or GLUC assay buffer. Typically, five µl of supernatant was
harvested and mixed with 25 µl coelenterazine in 384-well plates
or 50 µl of coelenterazine in 96-well plates. All experiments were
performed in triplicates except the siRNA screen that was done in
quadruplicates.
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Cell Viability Assay
Cellular Viability was assessed using the Cell Counting Kit
(CCK8, Sigma). Briefly, 5 µl of CCK8 solution was added in
50 µl PBS to the cells and incubated for 60 min at 37◦C prior
to measurement of absorbance at 450 nm in the Envision II.
Protein Purification
Recombinant proteins were purified from bacteria as described
previously (Prak et al., 2016). Protein expression and purification
of LC3B-GST, ATG4B, and ATG4B mutant C74S was done as
described previously (Pengo et al., 2017). Protein expression
and purification of ATG4B mutants 11–24, S34A and S34D
were done the same way as that of ATG4B. GST was
removed from GST-tagged ATG4B and GST-tagged ATG4B
mutants using PreScission Protease (GE Healthcare, 27-0843-
01). All recombinant proteins were stored at −80◦C in
50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.5 mM EDTA,
0.1 mM EGTA, 33% glycerol and 1 mM dithiothreitol
(DTT).
In vitro Phosphorylation Assays
In vitro radioactive assays were performed by incubating 100 ng
recombinant ATG4B diluted in assay buffer (20 mM Tris-
HCl pH 7.5, 10 mM MgCl2, 5 mM DTT, 20 µM cold
ATP, 0.16 µM ATP [γ-32P] Perkin-Elmer NEG502A100UC)
in the presence of recombinant AKT2 (Sigma-Millipore) at
30◦C for the indicated time. The reaction was stopped by
adding 5X SDS Loading Buffer and boiling for 5 min.
Samples were loaded on NUPAGE Acrylamide gel (Invitrogen,
NP0321BOX). Gels were stained with InstantBlue Protein Stain
(Expedeon, ISB1L) before drying on filter paper and measuring
incorporated radioactivity by exposing on photographic film
(Bio-Rad).
LC3B-GST Cleavage Assay and Analysis
of Enzyme Kinetics for ATG4B and Its
Mutants
The cleavage assay was done at 37◦C in a reaction volume of
20 µl containing 1 mg/ml LC3B-GST and 0.004 mg/ml ATG4B
wide type and mutants 11–24, S34A and S34D in assay buffer
A (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 5 mM DTT) for
0.4–10 min. The reaction was stopped by adding the same volume
of 2X SDS Loading Buffer and boiling for 5 min. The sample
were analyzed on a 4–20% Mini-PROTEAN R© TGXTM Precast Gel
(Bio-Rad, 456 1096) and Coomassie Brilliant Blue Staining. The
images of the gels were scanned and the intensity of each protein
band were quantified using Fiji3 using the analyse >gel built-in
function. The percentage of the substrate that remain at each
reaction time point (% of remaining substrate, y-axis) equal to
optical density (OD) LC3-GST/(OD LC3-GST+ OD GST+ OD
LC3-I) × 100% was plotted versus the reaction time (s, x-axis)
and the curves were then fitted using the non-linear regression
method in R software, from which the time needed to catalyze
amount of substrate were derived.
3http://fiji.sc/Fiji
To analyze the enzyme kinetics for ATG4B and its mutants,
purified ATG4B and ATG4B mutants at 45.15 nM except mutant
C74S at 11.3 µM were incubated with twofold serial dilutions
of LC3B-GST from 39 to 2.4 µM in assay buffer A in a
reaction volume of 20 µl at 37◦C. The incubation time was
6 min for all except mutant C74S was incubated for 5 h.
The reaction was stopped by adding the same volume of 2X
SDS Loading Buffer and boiling for 5 min. The samples were
subjected to a 4–20% Mini-PROTEAN R© gel and the intensity
of protein bands were analyzed the same way as that of the
cleavage assay above. The initial velocity (µM/min, y-axis)
was calculated as the concentration of GST produced, which
was plotted versus the concentration of substrate LC3B-GST
before reaction (µM, x-axis). The curves were then fitted
using the non-linear regression method in R software, from
which the Vmax and Km (Michaelis constant) for each enzyme-
substrate reaction were derived. The kcat (catalytic constant)
was determined diving Vmax by the enzyme concentration. The
catalytic efficiency is defined as kcat/Km (inverse molar liter per
second).
RESULTS
Optimization of a Cell-Based ATG4B
Sensor for High-Throughput Screening
In order to set up a screen for small molecule regulators of
ATG4B, we used the previously described luciferase release
assay (Ketteler et al., 2008). This assay relies on non-
conventional release of Gaussia luciferase (GLUC) from cells
upon ATG4B-dependent cleavage of an ActinLC3B2dNGLUC
reporter construct (Figure 1). The amount of luciferase in
supernatants correlates with cellular ATG4B activity, making this
a very simple quantitative assay. We have recently confirmed that
non-conventional release of GLUC from cells is not dependent on
autophagosome formation, since ATG5 knockout cells are able
to release GLUC from cells (Luft et al., 2014). Thus, this assay is
suitable for screening for modulators of ATG4B-mediated LC3
cleavage.
First, we tested various autophagy-modulating compounds
for response in the luciferase release assay (Figure 2). In line
FIGURE 1 | Schematic of the luciferase release assay. A fragment of Gaussia
luciferase is linked to full-length LC3B2 and β-actin inside cells. Upon
cleavage of LC3B2 by ATG4B, Gaussia luciferase (dNGLUC) is released into
the supernatants and can be monitored as a correlate of cellular ATG4B
activity. The structure of native coelenterazine is shown.
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FIGURE 2 | Performance of the luciferase release assay. (A) Luciferase activity in relative light units (RLU) was monitored in supernatants (SN) of HEK293T cells
transfected with ActinLC3dNGLUC and treated with the indicated reagents or left (NT, not treated). (B) HEK293T cells transfected with dNGLUC (without ActinLC3
linker) were treated as in (A) and luminescence released into supernatants was measured as an indicator of general dNGLUC secretion. (C) Cell viability was
measured using the cell-counting kit 8 (CCK-8, Sigma). The same cells as in (A), were subjected to the CCK-8 cell viability assay by adding the cell viability reagent
for 60 min before reading the absorbance at 450 nm in the PerkinElmer Envision II. Lower absorbance values reflect low cell viability. (D) HEK293T cells were
transfected with ActinLC3dNGLUC and treated with the indicated reagents or DMSO as control. (E) HEK293T cells transfected with dNGLUC (without ActinLC3
linker) were treated as in (D) and luminescence released into supernatants was measured in the PerkinElmer Envision II. (F) Cell viability was measured as in (C) after
treatment with the indicated reagents. Baf, bafilomycin A; Rap, rapamycin. All results displayed are from three independent experiments and statistical significance
was determined using a two-sided paired T-Test (∗∗∗p < 0.001, ∗∗p < 0.01, and ∗p < 0.05). Error bars represent standard deviation.
with previous observations that ATG4B activity is highly redox-
dependent (Scherz-Shouval et al., 2007), we found that treatment
of cells with DTT can strongly activate the reporter, whereas
TABLE 1 | Ratios of luciferase released from cells expressing the
ActinLC3BdNGLUC reporter normalized by cell viability.
Treatment Ratio Luc/viability
DMSO 1.00 ± 0.26
DTT 1.84 ± 0.32
H202 0.66 ± 0.24
Baf 0.85 ± 0.10
EBSS 0.09 ± 0.04
NH4CI 1.07 ± 0.35
Rapamycin 1.84 ± 0.59
Data calculated from values in Figure 2. Displayed are mean values with standard
deviation.
treatment with H2O2 reduced reporter activity (Figure 2A).
To assess whether the treatment affected general dNGLUC
secretion, we expressed dNGLUC, which is constitutively
released independent of ATG4B. We observed that DTT did
not modulate secretion of dNGLUC and H2O2 moderately
reduced secretion (Figure 2B). This decrease in dNGLUC
secretion was due to strongly reduced cell viability upon
treatment with H2O2 whereas treatment with DTT only mildly
affected cell viability (Figure 2C). Overall, these results suggest
that redox regulation directly affects cellular ATG4B activity.
Other autophagy modulating treatments such as NH4Cl or
bafilomycin A1 had very little impact on cellular ATG4B
activity (Figure 2D), confirming that the luciferase release
assay specifically measures ATG4B activity and not general
autophagy activity or flux. Starvation by EBSS resulted in a
decrease in luciferase secretion from the ActinLC3dNGLUC
construct, but at the same time a decrease in general
dNGLUC secretion and cell viability (Figures 2A–C) as well,
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suggesting that the decrease in luciferase release is due to
reduced cell viability. Treatment with rapamycin had no
strong effect on luciferase release from the ActinLC3dNGLUC
reporter, but reduced both overall dNGLUC secretion and
cell viability (Figures 2D–F). Upon calculating the ratio of
luciferase release over cell viability, rapamycin was confirmed
as inducer of ATG4B activity (Table 1). In conclusion, the
ATG4B luciferase release assay specifically detects cellular ATG4B
activity such as redox-sensitive mechanisms. One caveat in
using this assay is that effects on cellular viability can reduce
the net release of luciferase from the reporter, but such
effects can be normalized by assessing the cellular viability in
parallel.
Next, we established that the assay is amenable to high-
throughput screening by determining the Z′ factor, a good
surrogate for assessing the robustness of an assay (Zhang et al.,
1999). In the absence of potent small molecule inhibitors or
activators of ATG4B, we used Brefeldin A as a well characterized
inhibitor of dNGLUC secretion (Luft et al., 2014). As shown
in Supplementary Figure S2, Brefeldin A resulted in a robust
reduction in secreted dNGLUC from cells. We determined the
Z′ factor as 0.46, which was within a suitable range for cellular
screening. We screened a collection of 30,000 compounds from
UCL Chemibank4 in 384-well format in triplicates. The raw
4www.ucl.ac.uk/chemibank
FIGURE 3 | STK683963 is a novel activator of ATG4B. (A) Structures of hit compound STK683963 and its analogs STK683964 and STK848088.
(B) HeLa-ActinLC3dNGLUC cells were treated with the hit compound STK683963 and two analogs (STK683964, STK848088) overnight at the indicated
concentrations and luciferase activity released into supernatants was monitored. Data expressed as fold of DMSO control. (C) HEK293T cells were transfected with
ActinLC3AdNGLUC or ActinLC3A-R70H-dNGLUC and treated overnight with DMSO or STK683963. Luciferase release was measured in the PerkinElmer Envision
II. A one-way ANOVA with Tukey’s multiple comparison test was applied to calculate significances (∗∗∗∗p < 0.0001 and ∗∗p < 0.01). (D) HeLa cells stably expressing
ActinLC3dNGLUC were treated with STK683963 in combination with N-acetyl cysteine (NAC) and luciferase release was monitored after an overnight incubation.
NT, not treated. All results displayed are from three independent replicates and statistical significance was determined using a two-tailed paired T-Test (∗∗∗p < 0.001
and ∗p < 0.05). Error bars represent standard deviation.
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FIGURE 4 | A cDNA and siRNA screen to identify kinases and phosphatases that regulate ATG4B activity. Schematic of the screening workflow. For each gene,
three different siRNA oligonucleotides were pooled together in each well and a transfection mix was dispensed into 384-well plates, where each quadrant
corresponds to one 96-well layout. For cDNA transfection, the library was re-arrayed from 96-well plates into 384-well plates and transfected onto the reporter cell
line. A total of 15 siRNA plates (11 kinase and 4 phosphatase plates) were screened in quadruplicates and the cDNA library was screened in triplicates.
Supernatants (SN) were collected 48 h after transfection and measured on the PerkinElmer Envision II. All raw values were put into CellHTS2 for statistical analysis
and hits were identified based on ranking of the normalized values.
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luminescence values in the supernatants were normalized to the
plate median and a B score analysis was applied to account for
possible edge effects (Supplementary Figure S2).
A strong activator of cellular ATG4B activity identified in
the screening was the compound STK683963 (Figure 3A).
STK683963 strongly up-regulates the luciferase release reporter
in a dose-dependent manner (Figure 3B) after 24 h. The
analogous compound STK683964 showed slightly higher
luciferase values in a similar concentration range in activating
ATG4B, whereas another analog STK848088 did not. The
effect of STK693963 on increasing ATG4B activity is most
likely indirect since the increase in luciferase was only seen
after overnight treatment and not at earlier time points. Also,
STK693963 had no effect on in vitro ATG4B-mediated cleavage of
a LC3B-GST reporter (data not shown). One possibility was that
the compound might enhance ATG4B transcription. However,
STK683963 does not activate ATG4B transcript expression since
we could not observe an increase in the transcriptional activation
of an ATG4B-promoter-luciferase construct (Supplementary
Figure S3), while the positive control, Biochanin A, resulted in
an increase in luciferase expression. STK683963 had no effect
on viability of HeLa cells (Supplementary Figure S4). Next,
we tested whether STK683963 can overcome LC3A deficiency
that is associated with the R70H cancer mutation (Costa et al.,
2016). When LC3A R70H was inserted in the ActinLC3dNGLUC
reporter to monitor cleavage of this mutant, we observed that
ATG4B-mediated processing was mildly reduced (Figure 3C).
However, treatment with STK683963 activated LC3A R70H
processing, suggesting that it can be used to enhance LC3
processing deficiencies in some conditions. In order to identify a
possible mechanism of action for STK6983963, we investigated
whether it might act on the redox mechanism of ATG4B. Thus,
we treated cells with N-acetyl cysteine (NAC), a reducing agent
that was previously shown to affect LC3 processing (Heintze
et al., 2016). We found that STK683963 strongly activated
luciferase release, which was completely blocked in the presence
of NAC (Figure 3D). Thus, we propose that STK683963 acts as a
mediator of redox-regulation of ATG4B in cells and is a strong
activator of cellular ATG4B activity.
siRNA Screening to Identify Regulators
of ATG4B Activity
Having established that the luciferase reporter is amenable to
large-scale screening, we reasoned that this assay is well suited
to identify regulators of ATG4B activity in cells. We therefore
screened siRNA libraries targeting the human kinome and
human phosphatome and a cDNA overexpression library of
human kinases in HEK293T cells stably expressing the luciferase
release construct (Figure 4). By reverse transfection, we seeded
HEK293T-ActinLC3dNGLUC cells into 384-well plates on top of
the siRNA transfection mix using an automated workflow. As a
negative control, cells were left untransfected, and as a positive
control, we transfected cDNA expressing ATG4B in the last
column. The cells were incubated for 48h to achieve knockdown
of the target genes, prior to harvesting the supernatants and
analysis of luciferase activity in the PerkinElmer Envision II
plate reader. Raw values were normalized to plate median and
ranked by Z score. The robustness of the screen was assessed in
four replicates, and overall standard deviations showed that the
results were highly reproducible. The code used in R package
for analysis is shown in Supplementary File S3. The complete
set of results from the siRNA screen displaying activators and
inhibitors is shown in Supplementary File S4. Several strong
inhibitors of ATG4B activity were observed (knockdown of these
genes resulted in an increase of luciferase activity). These include
VRK1, TYK2, TRIB1, STK11, GUCY2B, and CAMK2D with a
significant Z score above 4 (Table 2). Interestingly, CAMK2D was
previously reported in another siRNA screen as inhibitor of LC3
puncta formation (Szyniarowski et al., 2011), in agreement with
our results and suggesting it may control pro-LC3 processing.
The strongest inhibition was seen upon knockdown of PAK1
(Z score = −2.85). Overall, a higher number of genes resulting
in activation upon knockdown than inhibition were identified.
AKT2 Activates ATG4B-Mediated LC3
Processing
In parallel to the siRNA screen, we also performed a cDNA
overexpression screen using the luciferase reporter assay
(Supplementary Figure S5). For cDNA expression screening, we
combined the four 96-well plates of the human kinome library
into one 384-well plate and transfected this in triplicates in
HEK293T-ActinLCdNGLUC cells. We identified a number of
activators and inhibitors of ATG4B-mediated luciferase release
(Supplementary File S5). We were particularly interested in
AKT2 since AKT1 has previously been shown to be involved in
autophagy and mitophagy (Ni et al., 2018; Soutar et al., 2018).
First, we transfected AKT2 in the ActinLC3dNGLUC reporter cell
line, concomitantly with ULK1, a kinase we recently identified as
a negative regulator of ATG4B activity and measured luciferase
release (Pengo et al., 2017). As expected, ULK1 significantly
reduced ATG4B-mediated LC3 processing, whereas AKT2
overexpression activated the luciferase reporter (Figure 5A). In
order to determine potential phosphorylation sites in ATG4B,
we used the scansite algorithm to search for AKT2 target sites
TABLE 2 | Hits from siRNA screening.











The top 10 inhibitors, where knockdown increases luciferase release from cells are
shown and their Z score after normalization calculated from the median of four
replicates. For full details including statistics, see Supplementary File S4.
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FIGURE 5 | AKT2 activates ATG4B. (A) HEK293T cells stably expressing ActinLC3dNGLUC were transfected with cDNA for ULK1 or AKT2 and luciferase activity
was monitored as described. ULK1 strongly inhibited luciferase release, while AKT2 activated the reporter. Results displayed are from three independent replicates
and statistical significance was determined using a two-sided paired T-Test (∗∗∗p < 0.001). (B) Prediction of AKT2 phospho-target sites from Scansite
(www.scansite.mit.edu). The ATG4B protein sequence (UniProt ID Q9Y4P1) was used as input and prediction was performed at low stringency. Serine 34 and Serine
121 were predicted as potential phosphorylation sites for AKT2. (C) Coomassie gel of the purified proteins. Equal amounts of the proteins were used as input in the
following experiments. (D) HEK293T cells stably expressing ActinLC3dNGLUC were transfected with pEAK12-GFP as a control, or wild-type (wt) ATG4B and its
mutants (C74S, S34D, and S34A). Luciferase activity in supernatants was monitored as described (∗∗p < 0.01 and ∗p < 0.05). (E) GST-LC3 cleavage assay to
determine time kinetics for 0.004 mg/ml of ATG4B and mutants (without GST-tag) to catalyze 50% of 1 mg/ml substrate LC3B-GST (see section “Materials and
Methods”). (F) The catalytic kinetics were determined after incubation of the purified enzyme with LC3B-GST at 37◦C from three different experiments and % of
remaining substrate is shown.
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(Obenauer et al., 2003). Scansite can generate predictions of
protein residues that are phosphorylated by protein kinases
based on data derived from experimental peptide arrays. Two
sites in ATG4B were predicted as potential AKT2 target site,
Serine 34 and Serine 121 (Figure 5B). One of these sites,
Serine 34 was previously reported as a target of AKT1-mediated
phosphorylation (Ni et al., 2018). Therefore, we generated
mutants of ATG4B that either cannot be phosphorylated (S34A)
or that mimic constitutive phosphorylation (S34D) (Figure 5C)
and investigated the consequence of S34A and S34D mutation on
cellular ATG4B activity. Indeed, ATG4B S34A showed reduced
ATG4B activity in the luciferase release assay, although higher
than the catalytic mutant C74S, whereas S34D showed higher
activity than WT ATG4B (Figure 5D), in line with a potential
role for AKT in positively regulating the activity of ATG4B.
Additionally, we saw that both an N-terminal deletion mutant
(11–24) and the S34D mutant exhibited increased LC3 substrate
cleavage in vitro using the LC3-GST assay (Figure 5E). The
calculation of the Km values of mutants compared to ATG4B
WT was 2.15, 1.74, 1.86, and 2.55 × 10−5 for ATG4B WT,
11–24, S34D and S34A, respectively (Figure 5F and Table 3).
Overall, these results suggest that post-translational modification
of Serine 34 in ATG4B might influence the LC3B processing
kinetics.
Next, in order to assess whether ATG4B can be
phosphorylated by AKT2, we performed an in vitro kinase
assay (Figure 6). In addition to ATG4B S34A, we also generated
two other mutants, ATG4B S121A and S262A (Figure 6A). We
detected a phosphorylation signal in the presence of AKT2 but
not in the presence of another control kinase (CLK2) indicating
that AKT2 can phosphorylate ATG4B in vitro (Figures 6B,C).
However, phosphorylation was also evident in the ATG4B S34A
mutant, suggesting that there are other phosphorylation sites in
ATG4B. Indeed, when assaying the S121A and S262A mutants,
we observed a strong decrease in phosphorylated ATG4B S121A
and S262A, indicating that these sites might be targets for AKT2,
at least in vitro (Figure 6C). Overall, our results suggest that
multiple sites in ATG4B can be phosphorylated by AKT2, all
potentially contributing to the regulation of activity.
DISCUSSION
The autophagy machinery has the delicate task to co-ordinate
the initiation and formation of an autophagosome under basal
conditions and upon stresses that induce autophagy. How these
TABLE 3 | Enzyme kinetics of in vitro cleavage assay.
Km (M) STDV Kcat/Km (1/M.S) STDV
WT 2.14957E-05 3.21287E-07 73758.29226 1955.269708
11-14 1.74178E-05 4.47812E-06 86959.80316 1099.428911
34A 1.86258E- 05 4.51334E-06 65214.59464 7583.879041
34D 2.54884E-05 6.56644E-06 83324.94999 5185.885677
The indicated ATG4B mutants were incubated with GST LC3B substrate and
subjected to in vitro cleavage as described in the “Materials and Methods” section.
events – from initiation to fusion with the lysosome – are
controlled is only poorly understood. It has recently been
suggested that the spatio-temporal control may be regulated by
post-translational modification of specific autophagy proteins
(Pengo et al., 2017; Sanchez-Wandelmer et al., 2017). Therefore,
we set out to get a better understanding of the post-translational
regulation of ATG4B, one of the key enzymes that co-ordinate the
processing of LC3/GABARP family of proteins.
Multiple factors that regulate ATG4B activity are starting to
emerge. A key regulator of ATG4 activity is redox-regulation,
which was initially shown to modulate the de-lipidation reaction
(Scherz-Shouval et al., 2007). It is now well established that
oxidation of a cysteine residue in proximity to the catalytic site
reduces LC3 processing. How this redox regulation is established
in cells is less well understood, but it is thought that sub-
cellular areas of increased ROS production may specifically affect
local ATG4 activity. In line with this, thioredoxin and NADPH
regulating enzymes such as Ribose-5-phosphate isomerase have
been linked to ATG4-mediated LC3 processing (Perez-Perez
et al., 2014, 2016; Heintze et al., 2016). It is thus not surprising
that compounds that modulate redox signaling may affect cellular
ATG4B activity. However, no small molecule compound activator
of ATG4B has been identified to date. Here, we have shown
that STK683963 and analogs are strong activators of cellular
ATG4B activity. We only observed activation after overnight
treatment and not at earlier time points (data not shown),
suggesting that the compound may not act directly on ATG4B,
but rather through indirect mechanisms. Furthermore, treatment
with NAC – a reducing agent – blocked the activation of cellular
ATG4B activity, hypothesizing that STK683963 primarily acts
through a redox-regulated mechanism. The identification of this
ATG4B enhancing compound provides a very useful tool that
may have applications in conditions where reduced ATG4 activity
or reduced LC3 processing has been observed (Costa et al., 2016).
In addition to redox mechanisms, phosphorylation of ATG4
family members is emerging as an important step in the
regulation of cellular autophagy. The first evidence for this
concept came from the observation that two residues, Ser383 and
Ser392, were phosphorylated in cells, but the underlying kinase
responsible has not been identified (Yang et al., 2015). In addition,
multiple kinases are known to directly regulate and/or bind to
ATG4B: ULK1/ATG1 mediated phosphorylation reduces ATG4B
activity in mammalian cells (Pengo et al., 2017) and ATG4 activity
in yeast (Sanchez-Wandelmer et al., 2017). AKT1 can bind to and
phosphorylate Ser34 in ATG4B (Ni et al., 2018), but the effects on
ATG4B activity have not been fully addressed. Recently, MST4
has been shown to phosphorylate Ser383 (Huang et al., 2017).
Overall, these findings point to a complex regulation of ATG4B
activity by kinases, and it is possible that such phospho-regulation
may be dependent on the sub-cellular localisation of the kinase
(Sanchez-Wandelmer et al., 2017).
High-throughput screens to identify regulators of autophagy
have previously been performed. The screens published to
date utilize siRNA libraries in phenotypic assays, studying the
formation of the autophagosome either through immunostaining
or a fluorescent protein reporter linked to LC3 (Chan et al.,
2007; Lipinski et al., 2010a,b; Szyniarowski et al., 2011; McKnight
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FIGURE 6 | In vitro kinase assay. (A) Coomassie gel showing the purified proteins used in the in vitro kinase activity assays. (B) Recombinant ATG4B or ATG4B
S34A was incubated with recombinant AKT2 and ATP γ-32P and incorporation of labeled γ-32P was measured by auto-radiography. The upper band corresponds
to AKT2 auto-phosphorylation and the lower band corresponds to ATG4B. (C) Recombinant ATG4B wild-type (WT), S121A or S262A were incubated with (+) or
without (–) recombinant AKT2 and incorporation of labeled γ-32P was measured by auto-radiography. On the left side, ULK1 mediated phosphorylation of ATG4B
was included as control. On the right side, CLK2 (CLK2 catalytic domain with GST-tagged (Prak et al., 2016)) was included as another protein control to show that in
the absence of ATG4B, AKT2 resulted in auto-phosphorylation.
et al., 2012). Here, we present the first siRNA- and cDNA-
based screen that interrogates the function of ATG4B, using a
luciferase-based readout. We have identified multiple kinases
and phosphatases that regulate ATG4B activity. In particular,
AKT2 is a novel gene that activates ATG4B, and promises to
be an interesting candidate for future studies. The AKT family
of proteins are known to regulate autophagosome formation
and mitophagy (Soutar et al., 2018), and AKT1 has recently
been shown to directly phosphorylate ATG4B at Ser34 (Ni
et al., 2018). However, it has not been assessed whether this
phosphorylation resulted in an increase or decrease of ATG4B
activity. In agreement, we identified AKT2 as an activator of
ATG4B in our cDNA expression screen. Of note, the two
homologs AKT1 and AKT3 were not present in the cDNA
library that we used. We noted that a S34A mutant displayed
reduced ATG4B activity, while a S34D phospho-mimetic mutant
showed an increase in ATG4B activity (Figure 5). We identified
other potential AKT2-mediated phosphorylation sites within
ATG4B at serine 121 and serine 262. Our assays do not rule
out the phosphorylation of serine 34, since this may be masked
by the two other sites in our assay. However, at this point
we cannot attribute the AKT2-mediated activation of cellular
ATG4B activity to a single phosphorylation site within ATG4B.
Overall, our findings point to a complex level of regulation by
the AKT family of protein kinases, which will require further
investigation.
In summary, we provide here a dataset from small molecule,
siRNA and cDNA screening that identified novel inhibitors and
activators of cellular ATG4B activity and we share this data with
the community for further investigations.
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FIGURE S1 | Sequence of the ATG4B promoter in the pLightSwitch vector
(Switchgear Genomics, CA).
FIGURE S2 | Small molecule screen for inhibitors and activators of cellular ATG4B
acPvity. (A) HeLa cells stably expressing ATG4B (4B) displayed a strong activation
of luciferase release into supernatants (SN) that was reduced in cells treated with
Brefeldin A (BA). A Z′ factor for ATG4B + BA compared to ATG4B + DMSO was
calculated for samples in a 384-well plate format and determined as 0.46.
(B) Distribution of hits in the small molecule screen. Activators of ATG4B are
shown on the left of the graph, and inhibitors on the right. (C) Distribution of raw
value counts for each plate (triplicates of each plate, left panel) and values
normalized to plate median (right panel). Over time, it was noted that the reporter
cells showed an increase in basal luciferase release. We therefore decided to
generate a new stable cell line after plate 44 that was more robust. Results
displayed are from three independent replicates and statistical significance was
determined using a two-sided paired T-Test (∗∗∗p < 0.001).
FIGURE S3 | STK683963 does not activate the ATG4B-luciferase promoter
construct. HEK293T cells were transfected with pLightSwitch-ATG4B luciferase
and renilla luciferase activity was measured after 24 h. Biochanin A (Bioch) and
Genistein (Genist) significantly up-regulater promoter-dependent luciferase,
whereas STK683963 has no effect on ATG4B promoter activity. RLU, relative light
unit. Results displayed are from three independent replicates and statistical
significance was determined using a two-tailed paired T-Test (∗∗p < 0.01,
∗p < 0.05).
FIGURE S4 | HeLa-ActinLC3dNGLUC cells were treated with the indicated
concentrations of STK683964 overnight and cell viability was determined using
the cell counting kit 8 (CCK8). No obvious effect on viability was observed at the
indicated concentrations.
FIGURE S5 | cDNA expression screen. (A) Heatmap of normalized luciferase
values in the 384-well plate. The four 96-well plates of the cDNA human kinome
library was pooled into one 384-well plate and 100 ng/well was transfected in
HEK293T-ActinLC3dNGLUC cells. Positive (ATG4B transfection) and negative
(untransfected) controls were included in the last two columns of the plate. (B)
Distribution of samples relative to positive (red color) and negative controls (blue
color). (C,D) The raw values were normalized to plate median and a B score
calculation was applied. The distribution of positive and negative controls is shown
in the left and right panel. The Z′ factor for this replicate was 0.41.
FILE S1 | Information about the human kinase and human phosphatase siRNA
libraries, including gene names and sequences for all siRNA oligonucleotides.
FILE S2 | Information about the human kinase cDNA library.
FILE S3 | R code used for statistical analysis of siRNA screening data.
FILE S4 | Raw and normalized data from siRNA screening.
FILE S5 | Raw and normalized data from cDNA overexpression screening.
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